Galapagos FY2024 EPS Estimate Decreased by Leerink Partnrs

Galapagos NV (NASDAQ:GLPG) – Analysts at Leerink Partnrs decreased their FY2024 EPS estimates for Galapagos in a research note issued on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings per share of ($0.48) for the year, down from their prior estimate of $0.08. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Galapagos’ current full-year earnings is $0.90 per share. Leerink Partnrs also issued estimates for Galapagos’ Q4 2024 earnings at ($0.14) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($1.77) EPS.

Several other research analysts also recently weighed in on the stock. Royal Bank of Canada lowered their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday. Leerink Partners assumed coverage on Galapagos in a research report on Monday, September 9th. They issued a “market perform” rating and a $24.00 price target for the company. Finally, Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. According to MarketBeat.com, Galapagos has a consensus rating of “Hold” and an average target price of $30.75.

Galapagos Trading Down 0.7 %

Shares of NASDAQ:GLPG opened at $26.71 on Monday. Galapagos has a 52-week low of $24.16 and a 52-week high of $42.46. The business’s 50 day simple moving average is $29.24 and its two-hundred day simple moving average is $27.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GLPG. BNP Paribas Financial Markets lifted its position in shares of Galapagos by 783.6% during the 1st quarter. BNP Paribas Financial Markets now owns 5,328 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 4,725 shares during the last quarter. Headlands Technologies LLC lifted its stake in Galapagos by 949.3% during the first quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 712 shares during the last quarter. Monaco Asset Management SAM lifted its position in Galapagos by 148.3% in the 1st quarter. Monaco Asset Management SAM now owns 16,744 shares of the biotechnology company’s stock worth $539,000 after buying an additional 10,000 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Galapagos by 18.5% in the first quarter. Acadian Asset Management LLC now owns 15,186 shares of the biotechnology company’s stock worth $488,000 after buying an additional 2,366 shares in the last quarter. Finally, AlphaCentric Advisors LLC raised its stake in shares of Galapagos by 3.3% during the second quarter. AlphaCentric Advisors LLC now owns 108,500 shares of the biotechnology company’s stock worth $2,689,000 after acquiring an additional 3,500 shares in the last quarter. 32.46% of the stock is owned by institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.